XCUR$1.01-0.98%
Exicure, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$6.61M
Float & O/S:4.27M / 6.55M
Inst Own:2.1%
DilutionScan read 22 of EXICURE, INC.'s SEC filings and found 1 warrant series, 1 S-1 registration and 1 completed offering on file for XCUR. The latest dilution event on file is an offering on Sep 23, 2025. Analysis updated Oct 9, 2026.
Signal8 Summary
XCUR
Going-concern warning, cash nearly exhausted
Snapshot
Exicure is a micro-cap biotech with no revenue and a history of heavy losses: FY 2025 net loss was $4.9M, and the company burned $8.6M in free cash flow against just $1.7M in cash.
What's Happening Right Now
- : Nasdaq granted Exicure an extension through December 2, 2026 to regain compliance with the $2.5 million minimum stockholders' equity rule, but there's no assurance compliance will be achieved, and delisting could follow.
- : Exicure's Q2 2026 10-Q disclosed substantial doubt about its ability to continue as a going concern, with only $1.7M in cash, a fall below Nasdaq's minimum equity requirement, and a warning it could seek bankruptcy protection if it can't raise capital.
- : Exicure said it will issue about 172,058 shares to GPCR Therapeutics in August 2026 to settle a $1.0 million clinical milestone payment, using stock instead of cash to preserve its cash position.
